| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
5 companies
Vivo Capital Viii, LLC serves as a 10% Owner at VYNE and has filed Form 4s across 5 companies. Across recent SEC filings that breaks down to 14 buys and 49 sells. Those positions are worth an estimated $108.5M at current prices.
Historically, Vivo Capital Viii, LLC's trades have earned a middling insider score of 57/100 across 4 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +38.4%.
The biggest single holding is VYNE (~$74.5M) as 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 294,118 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2020 | CRNX Crinetics Pharmaceuticals, Inc. | 10% Owner | Sell | 13,460 | $22.80 | $306,888.00 | -0.4% | |
| Jan 31, 2020 | CRNX Crinetics Pharmaceuticals, Inc. | 10% Owner | Sell | 26,920 | $22.07 | $594,164.00 | -0.3% | |
| Mar 20, 2019 | CRNX Crinetics Pharmaceuticals, Inc. | 10% Owner | Sell | 417,000 | $22.25 | $9,278,250.00 | -11.2% | |
| Jul 20, 2018 | CRNX Crinetics Pharmaceuticals, Inc. | 10% Owner | Buy | 353,180 | $18.62 | $6,575,421.40 | +10.0% | |
| Jan 25, 2018 | VYNE Vyne Therapeutics Inc. | 10% Owner | Buy | 294,118 | $17.00 | $5,000,006.00 | New |